Details

Autor(en) / Beteiligte

• Martinez-Lopez, Joaquin
• Lahuerta, Juan J.
• Pepin, François
• González, Marcos
• Barrio, Santiago
• Ayala, Rosa
• Puig, Noemí
• Montalban, María A.
• Paiva, Bruno
• Weng, Li
• Jiménez, Cristina
• Sopena, María
• Moorhead, Martin
• Cedena, Teresa
• Rapado, Immaculada
• Mateos, María Victoria
• Rosiñol, Laura
• Oriol, Albert
• Blanchard, María J.
• Martínez, Rafael
• Bladé, Joan
• San Miguel, Jesús
• Faham, Malek
• García-Sanz, Ramón

Titel

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Ist Teil von

• Blood, 2014-05, Vol.123 (20), p.3073-3079

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• We assessed the prognostic value of minimal residual disease (MRD) detection in multiple myeloma (MM) patients using a sequencing-based platform in bone marrow samples from 133 MM patients in at least very good partial response (VGPR) after front-line therapy. Deep sequencing was carried out in patients in whom a high-frequency myeloma clone was identified and MRD was assessed using the IGH-VDJH, IGH-DJH, and IGK assays. The results were contrasted with those of multiparametric flow cytometry (MFC) and allele-specific oligonucleotide polymerase chain reaction (ASO-PCR). The applicability of deep sequencing was 91%. Concordance between sequencing and MFC and ASO-PCR was 83% and 85%, respectively. Patients who were MRD– by sequencing had a significantly longer time to tumor progression (TTP) (median 80 vs 31 months; P < .0001) and overall survival (median not reached vs 81 months; P = .02), compared with patients who were MRD+. When stratifying patients by different levels of MRD, the respective TTP medians were: MRD ≥10−3 27 months, MRD 10−3 to 10−5 48 months, and MRD <10−5 80 months (P = .003 to .0001). Ninety-two percent of VGPR patients were MRD+. In complete response patients, the TTP remained significantly longer for MRD– compared with MRD+ patients (131 vs 35 months; P = .0009). •MRD assessment by sequencing is prognostic of TTP and OS in multiple myeloma patients.•Among patients in complete response, MRD assessment by sequencing enables identification of 2 distinct subgroups with different TTP.